{"id":112421,"date":"2026-06-03T12:20:47","date_gmt":"2026-06-03T09:20:47","guid":{"rendered":"https:\/\/prizrenpost.com\/al\/terapia-e-re-kunder-kancerit-jep-shprese-te-madhe-te-disa-paciente-tumoret-u-zhduken-plotesisht\/"},"modified":"2026-06-03T12:20:47","modified_gmt":"2026-06-03T09:20:47","slug":"terapia-e-re-kunder-kancerit-jep-shprese-te-madhe-te-disa-paciente-tumoret-u-zhduken-plotesisht","status":"publish","type":"post","link":"https:\/\/prizrenpost.com\/al\/terapia-e-re-kunder-kancerit-jep-shprese-te-madhe-te-disa-paciente-tumoret-u-zhduken-plotesisht\/","title":{"rendered":"Terapia e re kund\u00ebr kancerit jep shpres\u00eb t\u00eb madhe: Te disa pacient\u00eb tumoret u zhduk\u00ebn plot\u00ebsisht"},"content":{"rendered":"
\"Terapia<\/figure>\n

Pas rezultateve q\u00eb po t\u00ebrheqin v\u00ebmendjen n\u00eb ASCO 2026, studiuesit po e zgjerojn\u00eb testimin e amivantamab edhe n\u00eb faz\u00ebn e tret\u00eb klinike, nd\u00ebrsa pritjet p\u00ebr k\u00ebt\u00eb trajtim po rriten ndjesh\u00ebm<\/p>\n

Nj\u00eb trajtim i ri kund\u00ebr kancerit po konsiderohet si nj\u00eb nga zhvillimet m\u00eb premtuese t\u00eb viteve t\u00eb fundit n\u00eb onkologji, pasi rezultatet e nj\u00eb prove klinike kan\u00eb treguar se te disa pacient\u00eb tumoret jan\u00eb zhdukur plot\u00ebsisht.<\/p>\n

B\u00ebhet fjal\u00eb p\u00ebr amivantamab, nj\u00eb terapi me veprim t\u00eb dyfisht\u00eb ndaj receptor\u00ebve EGFR dhe MET, e cila po testohet te pacient\u00ebt me kancer t\u00eb avancuar t\u00eb kok\u00ebs dhe qaf\u00ebs, te t\u00eb cil\u00ebt s\u00ebmundja ishte rikthyer ose nuk po reagonte m\u00eb ndaj trajtimeve standarde.<\/p>\n

Sipas t\u00eb dh\u00ebnave t\u00eb raportuara nga The Guardian dhe t\u00eb prezantuara n\u00eb ASCO 2026, n\u00eb studimin OrigAMI-4 mor\u00ebn pjes\u00eb 102 pacient\u00eb. Rezultatet treguan se 42 p\u00ebr qind e tyre pat\u00ebn p\u00ebrgjigje ndaj trajtimit, nd\u00ebrsa te 15 p\u00ebr qind u raportua zhdukje e plot\u00eb e tumorit.<\/p>\n

Ekspert\u00ebt e cil\u00ebsojn\u00eb k\u00ebt\u00eb si nj\u00eb rezultat jasht\u00ebzakonisht t\u00eb r\u00ebnd\u00ebsish\u00ebm, sidomos p\u00ebr pacient\u00ebt me forma agresive t\u00eb s\u00ebmundjes, t\u00eb cil\u00ebt zakonisht kan\u00eb shum\u00eb pak mund\u00ebsi terapeutike pasi kanceri p\u00ebrparon pas kimioterapis\u00eb ose imunoterapis\u00eb, transmeton Telegrafi.<\/p>\n

Amivantamab vepron duke bllokuar dy rrug\u00eb t\u00eb r\u00ebnd\u00ebsishme q\u00eb ndihmojn\u00eb rritjen dhe p\u00ebrhapjen e tumorit, nd\u00ebrsa nj\u00ebkoh\u00ebsisht ndihmon sistemin imunitar t\u00eb njoh\u00eb dhe sulmoj\u00eb qelizat kanceroze. Kjo qasje e kombinuar \u00ebsht\u00eb arsyeja pse terapia po t\u00ebrheq kaq shum\u00eb v\u00ebmendje n\u00eb komunitetin shkencor.<\/p>\n

Nj\u00eb tjet\u00ebr zhvillim i r\u00ebnd\u00ebsish\u00ebm \u00ebsht\u00eb se tashm\u00eb ka nisur edhe studimi i faz\u00ebs s\u00eb tret\u00eb, OrigAMI-5, i cili do ta testoj\u00eb k\u00ebt\u00eb terapi n\u00eb nj\u00eb grup m\u00eb t\u00eb madh pacient\u00ebsh dhe n\u00eb nj\u00eb faz\u00eb m\u00eb t\u00eb hershme t\u00eb trajtimit. Kjo faz\u00eb konsiderohet vendimtare p\u00ebr t\u00eb kuptuar n\u00ebse rezultatet mund t\u00eb konfirmohen n\u00eb shkall\u00eb m\u00eb t\u00eb gjer\u00eb.<\/p>\n

Megjith\u00ebse t\u00eb dh\u00ebnat jan\u00eb shum\u00eb inkurajuese, studiuesit theksojn\u00eb se ende nevojiten prova m\u00eb t\u00eb gjera dhe ndjekje m\u00eb e gjat\u00eb e pacient\u00ebve p\u00ebr t\u00eb vler\u00ebsuar p\u00ebrfitimin afatgjat\u00eb, sigurin\u00eb dhe mund\u00ebsin\u00eb e p\u00ebrdorimit m\u00eb t\u00eb gjer\u00eb klinik.<\/p>\n

Aktualisht, rezultatet po shihen si nj\u00eb hap i r\u00ebnd\u00ebsish\u00ebm p\u00ebr pacient\u00ebt me kancer t\u00eb avancuar t\u00eb kok\u00ebs dhe qaf\u00ebs, por edhe si nj\u00eb sinjal shprese p\u00ebr zhvillimin e terapive t\u00eb reja m\u00eb t\u00eb personalizuara kund\u00ebr kancerit.<\/p>\n

\n

Burimi: mesazhi<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Pas rezultateve q\u00eb po t\u00ebrheqin v\u00ebmendjen n\u00eb ASCO 2026, studiuesit po e zgjerojn\u00eb testimin e amivantamab edhe n\u00eb faz\u00ebn e tret\u00eb klinike, nd\u00ebrsa pritjet p\u00ebr k\u00ebt\u00eb trajtim po rriten ndjesh\u00ebm Nj\u00eb trajtim i ri kund\u00ebr kancerit po konsiderohet si nj\u00eb nga zhvillimet m\u00eb premtuese t\u00eb viteve t\u00eb fundit n\u00eb onkologji, pasi rezultatet e nj\u00eb prove […]<\/p>\n","protected":false},"author":1,"featured_media":112420,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-112421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-shendetesi"],"_links":{"self":[{"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/posts\/112421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/comments?post=112421"}],"version-history":[{"count":0,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/posts\/112421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/media\/112420"}],"wp:attachment":[{"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/media?parent=112421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/categories?post=112421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prizrenpost.com\/al\/wp-json\/wp\/v2\/tags?post=112421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}